

PROGRESSIVE'S EVENING STROLL

DATE: 16 June, 2026

Market Snapshot:

After a strong start, the Index remained within a range for most of the session before breaking out in the final session to close at 23,989.15 with gains of 135.25 points. Among the sectors, Realty extended its outperformance by soaring 2.26%, followed by IT and Media, while Metal and Auto lagged. Mid and Smallcaps, with gains of 0.41% and 0.42%, respectively, marginally underperformed Nifty50.

HOW THE DAY TRENDED



INDICES

Index	Close	Points	%Chg.
Sensex	76808.48	544.15	0.71
Nifty50	23989.15	135.25	0.57
Nifty Midcap 100	61802.05	252.40	0.41
Nifty Small Cap 100	18477.75	77.75	0.42

SECTORAL GAINERS / LOSERS

Sectors	Close	Points	%Chg.
NIFTY REALTY	818.10	18.05	2.26
NIFTY IT	28568.10	500.20	1.78
NIFTY AUTO	26891.55	(85.95)	(0.32)
NIFTY METAL	12881.50	(202.35)	(1.55)

NIFTY TOP GAINERS / LOSERS

Gainers	CMP (Rs)	%Chg.	Losers	CMP (Rs)	%Chg.
HCL TECH	1159.00	3.55	HINDALCO	982.40	(3.11)
TATA CONSUMER	1130.90	2.77	JSW STEEL	1274.30	(1.71)
NTPC	355.55	2.14	HDFC LIFE	574.40	(1.17)
BAJAJ FINSERV	1787.30	2.12	APOLLO HOSPITAL	8390.50	(0.92)

INDICES LEVELS FOR June 17, 2026

Nifty (future)		Bank Nifty (future)	
Resistance	24100	Resistance	57800
Support	23900	Support	57000



KEY TAKEAWAYS OF THE DAY

◆ **HCLTech to buy 10.5% stake in Sarvam AI, valuing startup at USD1.5bn:**

HCLTech will acquire a 10.5% stake in domestic generative AI startup Sarvam AI for Rs14.27bn in cash, leading the firm's Series B round as a strategic investor. Sarvam was valued at USD1.5bn in the round, which raised USD234mn in its first close out of a targeted USD300mn. The investment will allow the Indian IT services company to develop specific language models and AI solutions for its global client base, and accelerate the development of sovereign AI solutions for governments and regulated industries.

◆ **GIC OFS: Govt to sell 5% stake at Rs352/share:**

The government will sell up to 5% stake in General Insurance Corporation of India (GIC) at a floor price of Rs352/-per share. At the floor price of Rs352 apiece, the sale of over 8.77 crore shares will fetch about Rs3,000cr to the exchequer. The government will divest 2% equity in GIC, with an additional 3% as a green shoe option. The government hopes to exceed the budgeted target of Rs80,000cr from PSU disinvestment and asset monetisation in the current fiscal.

◆ **Yes Bank and Northern Arc Capital partner to bridge India's credit gap:**

Yes Bank & Northern Arc Capital have entered a partnership to expand access to credit, scale digital lending and provide debt investment opportunities for its customers. This brings together balance-sheet strength, digital infrastructure, distribution capabilities, underwriting expertise, and technology platforms to expand formal credit access across underserved segments in India, in line with the Government of India's Financial Inclusion agenda towards fulfilling the Viksit Bharat vision of 2047.

◆ **Novartis India launches Pluvicto for prostate cancer treatment:**

Novartis launched Pluvicto, a treatment that delivers radiation directly to cancer cells while limiting damage to healthy tissue. Pluvicto drug is administered as an intravenous infusion, and is approved for patients diagnosed with a specific, hard-to-treat form of the disease called Prostate-Specific Membrane Antigen (PSMA)-positive metastatic castration-resistant prostate cancer. It is imported from certified manufacturing facilities in Spain and Italy.

◆ **Piramal Pharma to stay away from generic GLP-1 race amid global rush:**

Piramal Pharma is staying away from the increasingly crowded generic GLP-1 peptide manufacturing market, despite the global rush into obesity drug supply chains. Instead, it is choosing to focus on niche, higher margin peptide opportunities as it prepares for a recovery in its contract development and manufacturing (CDMO) business. The company is focusing on specialised, science-led peptide opportunities, rather than large-scale commodity manufacturing linked to blockbuster obesity drugs such as semaglutide and tirzepatide.

Source: Media Reports



DISCLAIMERS AND DISCLOSURES-

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products.

PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859/Research Analyst BSE Enlistment No. 5049. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report:-

- PSBPL or its associates financial interest in the subject company: NO
- Research Analyst (s) or his/her relative's financial interest in the subject company: NO
- PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company.
- PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months.
- The research analyst has served as officer, director or employee of the subject company: NO
- Registration granted by SEBI and certification from NISM is in no way guarantee performance of the intermediary or provide any assurance of returns to investors

PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Terms & Conditions:

This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and its at discretion of the clients to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

Registered Office Address:

Progressive Share Brokers Pvt. Ltd,
122-124, Laxmi Plaza, Laxmi Indl Estate,
New Link Rd, Andheri West,
Mumbai—400053, Maharashtra
www.progressiveshares.com | Contact No.:022-40777500.

Compliance Officer:

Ms. Mamatha Poojari,
Email: compliance@progressiveshares.com,
Contact No.:022-40777500.

Grievance Officer:

Email: grievancecell@progressiveshares.com

